Chemistry:CUMYL-PICA
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C23H28N2O |
| Molar mass | 348.490 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CUMYL-PICA (SGT-56) is an indole-3-carboxamide based synthetic cannabinoid. It is the α,α-dimethylbenzyl analogue of SDB-006.[1] It was briefly sold in New Zealand during 2013 as an ingredient of at the time legal synthetic cannabis products, but the product containing CUMYL-BICA and CUMYL-PICA was denied an interim licensing approval under the Psychoactive Substances regulatory scheme, due to reports of adverse events in consumers.[2] CUMYL-PICA acts as an agonist for the cannabinoid receptors, with Ki values of 59.21 nM at CB1 and 136.38 nM at CB2 and EC50 values of 11.98 nM at CB1 and 16.2 nM at CB2.[3][4]
See also
References
- ↑ "Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA". ACS Chemical Neuroscience 11 (21): 3672–3682. November 2020. doi:10.1021/acschemneuro.0c00591. PMID 33054155.
- ↑ "The Risk Assessment Score Table. New Zealand Ministry of Health, 27 September 2013". http://www.health.govt.nz/system/files/documents/pages/risk-assessment-score-table-27sept-13.pdf.
- ↑ "Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA". The Journal of Pharmacology and Experimental Therapeutics 365 (2): 437–446. May 2018. doi:10.1124/jpet.117.246983. PMID 29549157. PMC 5932312. http://jpet.aspetjournals.org/content/early/2018/03/16/jpet.117.246983.
- ↑ Bowden MJ, Bernard WJ, "Cannabinoid compounds", WO patent 2014167530, published 11 April 2013
 |  |
